Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Shares Outstanding (Weighted Average) (2023 - 2025)

CG Oncology (CGON) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $77.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 23.69% year-over-year to $77.3 million, compared with a TTM value of $77.3 million through Dec 2025, up 23.69%, and an annual FY2025 reading of $77.3 million, up 23.69% over the prior year.
  • Shares Outstanding (Weighted Average) was $77.3 million for Q4 2025 at CG Oncology, up from $76.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $77.3 million in Q4 2025 and bottomed at $3.9 million in Q1 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $45.8 million, with a median of $58.6 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 1363.23% in 2024, then grew 23.69% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $4.3 million in 2023, then soared by 1343.03% to $62.5 million in 2024, then grew by 23.69% to $77.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CGON at $77.3 million in Q4 2025, $76.4 million in Q3 2025, and $76.2 million in Q2 2025.